Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

225 results about "Purine derivative" patented technology

The term "purine derivatives (PD)" refers to allantoin, uric acid, xanthine and hypoxanthine collectively. These are the degradation products from purines, purine bases and purine nucleosides.

Purine derivative

PCT No. PCT / JP97 / 02310 Sec. 371 Date Mar. 3, 1998 Sec. 102(e) Date Mar. 3, 1998 PCT Filed Jul. 3, 1997 PCT Pub. No. WO98 / 01448 PCT Pub. Date Jan. 15, 1998This invention relates to novel purine derivatives of formula (I): where R2 and R9 are hydrocarbon groups, R6 is an amino group and R8 is a hydroxyl, or acyloxy group. These purine derivatives are effective at promoting secretion of interferon in patients, and can be used to treat diseases against which interferon is effective.
Owner:SUMITOMO DAINIPPON PHARMA CO LTD

7-Substituted Purine Derivatives for Immunosuppression

The present invention provides novel purinone and related derivatives useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formula III:
Owner:WYETH LLC

N²-quinoline or isoquinoline substituted purine derivatives

Novel compound having the following formula: wherein W represents a hydrogen, an optionally substituted C1-6 alkyl, an optionally substituted C3-6 cycloalkyl, or an optionally substituted C1-6 haloalkyl, Y represents a hydrogen, or a saccharide, Q represents a quinoline or isoquinoline. Also disclosed are a pharmaceutical compositions comprising the same, methods for treating cancer using the same, and methods for the synthesis of the same.
Owner:WU NA +1

Fused purine derivatives

A condensed purine derivative represented by Formula (I): wherein X—Y-Z represents R1N—C═O or N═C—W, R2 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted alicyclic heterocyclic group or the like, n represents an integer of from 0 to 3, V1 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aromatic heterocyclic group, V2 represents a substituted lower alkyl group or a substituted or unsubstituted aromatic heterocyclic group, and when V1 represents a hydrogen atom, a lower alkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryl group, and for example, X—Y-Z represents R1aN—C═O and R2 represents a substituted lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted alicyclic heterocyclic group, a halogen atom, a lower alkylthio group, —NR7R8, —CO2H, a lower alkoxycarbonyl group, —COHal, —CONR9R10 or —CHO, V2 may represent a lower alkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryl group; or a pharmacologically acceptable salt thereof.
Owner:KYOWA HAKKO KOGYO CO LTD

Substituted 6-(alkylbenzylamino)purine derivatives for use as cytokinin receptor antagonists and preparations containing these derivatives

InactiveUS20100240537A1Reduced germinationIncreasing of yield and qualityBiocideOrganic chemistryThio-Purine
The invention relates to 6-(alkylbenzylamino)purine derivatives of the general formula I for use as cytokinin receptor antagonists, wherein R1 is selected from the group comprising hydroxyl, amino, nitro, thio and alkyl group, and R2 denotes one to four alkyl groups. The invention also relates to preparations containing these derivatives.
Owner:UNIV PALACKEHO V OLOMOUCI +1

Container and composition for enhanced gas barrier properties

ActiveUS20070082156A1Enhanced gas barrierAcceptable clarityReady-for-oven doughsSynthetic resin layered productsPolyesterPurine
A container comprising a polyester composition with enhanced carbon dioxide and oxygen barrier properties is provided. The polyester composition comprises a polyester and a purine derivative. In a particular embodiment, the purine derivative comprises a purine dione, such as caffeine.
Owner:THE COCA-COLA CO +1

Manufacturing Method Of Photosensitive Resin Composition And Solidified Embossing Pattern, And Semiconductor Device

The invention provides a manufacturing method of photosensitive resin composition capable of forming a solidifying film causing no color change even on copper or copper alloy. The invention also provides a manufacturing method of a solidified embossing pattern by adopting the photosensitive resin composition to form pattern, and a semiconductor device. The photosensitive resin composition includes by mass: (A) 100 parts of at least one resin selected from a group formed by polyamide acid and polyamide acid esters as polyimide precursor, and poly oxyamide, poly amino acid amide, polyamide, polyamide imide, polyimide, polybenzoxazole, imidite and polybenzothiazole as poly oxazole precursor; (B) 0.01 to 10 parts of purine derivatives; and (C) 1 to 50 parts of sensitizer.
Owner:ASAHI KASEI KK

Synthesis and methods of use of purine analogues and derivatives

A purine derivative or analogue comprises a 9-atom bicyclic moiety, moiety A, linked through a linker L to a moiety B, where B is a carboxylic acid, a carboxylic acid ester, or a moiety of the structure N(Y1)-D, where Y1 can be one of a variety of substituents, including hydrogen or alkyl, and D is a moiety that enhances the pharmacological effects, promotes absorption or blood-brain barrier penetration of the derivative or analogue. The moiety A has a six-membered ring fused to a five-membered ring. The moiety A can have one, two, or three nitrogen atoms in the five membered ring and has two nitrogen atoms in the six-membered ring. The moiety A can be a purine moiety. The moiety B can be one of a variety of moieties, including moieties having nootropic activity or other biological or physiological activity.
Owner:NEOTHERAPEUTICS

Adhesion promotion in printed circuit boards

Compositions and methods for enhancing adhesion between a copper conducting layer and a dielectric material during manufacture of a printed circuit board. Conditioning compositions contain a functional organic compound and preferably a transition metal ion. The functional organic compound, e.g., a purine derivative, is capable of forming a self-assembled monolayer. Adhesion promoting compositions contain an acid, preferably an inorganic acid, and an oxidant. The latter compositions may also contain a corrosion inhibitor and / or a transition metal ion selected from among Zn, Ni, Co, Cu, Ag, Au, Pd or another Pt group metal. The corrosion inhibitor may comprise a nitrogen-containing aromatic heterocyclic compound.
Owner:MACDERMID ENTHONE INC

Purine derivatives as a3 adenosine receptor-selective agonists

Disclosed are (N)-methanocarba adenine nucleosides, e.g., of formula (I) as highly potent A3 adenosine receptor agonists, pharmaceutical compositions comprising such nucleosides, and a method of use of these nucleosides, wherein R1-R6 are as defined in the specification. These nucleosides exhibit similar selectivities as agonists of the A3 versus the A1 receptor for both human and mouse adenosine receptors, and are contemplated for use in the treatment a number of diseases, for example, inflammation, cardiac ischemia, stroke, asthma, diabetes, and cardiac arrhythmias.
Owner:UNITED STATES OF AMERICA

Multilayer Container for Enhanced Gas Barrier Properties

ActiveUS20080113134A1Enhanced gas barrierAcceptable clarityReady-for-oven doughsFlexible coversPolymer sciencePurine derivative
A multilayer container having enhanced gas barrier properties comprises at least two outer layers comprising a polymer matrix, and at least one barrier layer disposed between the at least two outer layers. The at least one barrier layer comprises a first polymer composition comprising a polymer matrix and a low molecular weight additive. In a particular embodiment, the low molecular weight additive comprises a purine derivative, such as caffeine, and is present in the multilayer container in an amount in the range of about 0.2 to about 10 weight percent of the container.
Owner:THE COCA-COLA CO

Methods of treating hbv and hcv infection

InactiveUS20110150836A1Symptoms improvedReduction in rate of progressBiocidePeptide/protein ingredientsHepatitis c viralPurine
This application relates to a purine derivative and pharmaceutical compositions which are useful for treating a hepatitis B viral infection or a hepatitis C viral infection.
Owner:GILEAD SCI INC

Purine derivatives and their pharmaceutical uses

The present invention relates to compounds of formula (I):wherein;R1 represents hydrogen or C1-3alkyl;n is an integer having a value of 1 to 5;X represents O or NH;Y represents C or N;or a pharmaceutically acceptable salt thereof, have been shown to be inducers of human interferon and may possess an improved profile with respect to known inducers of human interferon, for example enhanced potency. The compounds of the invention may therefore be useful in the treatment of various disorders, in particular the treatment of infectious diseases, cancer, allergic diseases and other inflammatory conditions, and their use as vaccine adjuvants.
Owner:GLAXO SMITHKLINE LLC

Purine derivatives and methods of use thereof

The invention relates to Purine Derivatives; compositions comprising an effective amount of a Purine Derivative; and methods for treating or preventing an ischemic condition, reperfusion injury, a cellular proliferative disorder, a cardiovascular disease, a neurological disorder, a skin disorder, a radiation-induced injury, a wound, or an inflammatory disease comprising administering an effective amount of a Purine Derivative to a subject in need thereof.
Owner:INOTECK PHARMA CORP

Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases

The present invention relates to compounds of formula (I):wherein R1 is C1-6alkylamino, C1-6alkoxy, or C3-7cycloalkyloxy; m is an integer having a value of 2 to 6; R2 is hydrogen, C1-6alkyl, or C3-7cycloalkylC0-6alkyl; and salts thereof are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, the treatment of infectious diseases and cancer, and may also be useful as vaccine adjuvants.
Owner:GLAXO SMITHKLINE LLC

New purine derivatives

The present invention relates to compounds of formula 1 or pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is methyl, ethyl or isopropyl, and the other is H; R3 and R4 are each independently H, branched or unbranched C1-C6 alkyl, or aryl, and wherein at least one of R3 and R4 is other than H; R5 is a branched or unbranched C1-C5 alkyl group or a C1-C6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups; R6, R7, R8 and R9 are each independently H, halogen, NO2, OH, OMe, CN, NH2, COOH, CONH2, or SO2NH2. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, CNS disorders, diabetes, stroke, alopecia or neurodegenerative disorders.
Owner:CANCER RES TECH LTD

Purine derivatives having phosphodiesterase IV inhibition activity

A compound of the formula:whereinR3 represent a C1-8 alkyl which is unbranched or branched and unsubstituted or substituted with OH, alkoxy, CO2H, =NOH, =NOCONH2, or =O; C3-8 cycloalkyl which is unsubstituted or substituted with OH, alkoxy, CO2H, =NOH, =NOCONH2, or =O; C4-8 cycloalkylalkyl wherein the cycloalkyl portion is unsubstituted or substituted with OH, alkoxy, CO2H, =NOH, =NOCONH2, or =O; aryl which is unsubstituted or substituted with Cl, NH2, alkylamino, dialkylamino, amido, C1-C8 alkylamido, C1-C3 dialkylamido, OH, alkoxy, HC=NOH, HC=NOCONH2, C1-C3 alkyl, phenyl or benzyl; aralkyl (C1-4); heterocyclyl; heterocyclylalkyl (C1-C4); and heteroaryl;R8 represents H or a C1-8 alkyl which is unbranched or branched and unsubstituted or substituted with OH, alkoxy, CO2H, =NOH, =NOCONH2, or =O; C3-8 cycloalkyl which is unsubstituted or substituted with OH, alkoxy, CO2H, =NOH, =NOCONH2, or =O; C4-8 cycloalkylalkyl wherein the cycloalkyl portion is unsubstituted or substituted with OH, alkoxy, CO2H, =NOH, =NOCONH2, or =O; aryl which is unsubstituted or substituted with Cl, NH2, alkylamino, dialkylamino, amido, C1-C8 alkylamido, C1-C3 dialkylamido, OH, alkoxy, HC=NOH, HC=NOCONH2, C1-C3 alkyl, phenyl or benzyl; aralkyl (C1-4); heterocyclyl; heterocyclylalkyl (C1-C4); and heteroaryl.
Owner:EURO-CELTIQUE SA

Purine derivatives

The present invention relates to compounds of formula (I)or pharmaceutically acceptable salts thereof, wherein Q, G, ring A, ring B, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, and m are defined herein. The novel purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.
Owner:PFIZER INC

New purine derivatives

InactiveUS20060183760A1BiocideNervous disorderArylHalogen
The present invention relates to compounds of formula I or pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is methyl, ethyl or isopropyl, and the other is H; R3 and R4 are each independently H, branched or un branched C1-C6 alkyl, or aryl, and wherein at least one of R3 and R4 is other than H; R5 is a branched or unbranched C1-C5 alkyl group or a C1-C6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups; R6, R7, R8 and R9 are each independently H, halogen, NO2, OH, OMe, CN, NH2, COOH, CONH2, or SO2NH2. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, CNS disorders, diabetes, stroke, alopecia or neurodegenerative disorders.
Owner:CANCER RES TECH LTD

Purine derivatives and methods of use thereof

The present invention relates to Purine Derivatives; compositions comprising an effective amount of a Purine Derivative; and methods for reducing an animal's core body temperature, protecting an animal's heart against myocardial damage during cardioplegia; or for treating or preventing a cardiovascular disease, a neurological disorder, an ophthalmic condition, an ischemic condition, a reperfusion injury, obesity, a wasting disease, or diabetes, comprising administering an effective amount of a Purine Derivative to an animal in need thereof. The Purine Derivatives include compounds of the following formula:or a pharmaceutically acceptable salt thereofwhereinA is —CH2OHB and C are —OH:D isA and B are trans with respect to each other:B and C are cis with respect to each other:C and D are cis or trans with respect to each other:R1 is —H, -halo, —CN, —N(R2)2, —OR2, —SR2, —NHC(O)R2, —NHC(O)N(R2)2, —NHC(O)OR2, —C(O)OR2, —C(O)R2, —C(O)N(R2)2, —OC(O)N(R2)2, —C(halo)3, or —NO2;each R2 is independently —H, —C1-C10 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —(CH2)n-aryl, —(CH2)n-(3- to 7-membered monocyclic heterocycle, —(CH2)n-(8- to 12-membered bicyclic heterocycle), —(CH2)n—(C3-C8 monocyclic cycloalkyl), —(CH2)n—(C3-C8 monocyclic cycloalkenyl), —(CH2)n—(C8-C12 bicyclic cycloalkyl), or —(CH2)n—(C8-C12 bicyclic cycloalkenyl);each n is an integer ranging from 0 to 6;each p is an integer ranging from 1 to 6; andeach q is an integer ranging from 1 to 6.
Owner:INOTECK PHARMA CORP

Method for preparing purine derivatives

The invention provides a method for preparing an intermediate of trajenta and belongs to the technical field of pharmacy. The method comprises the following steps: reacting 8-bromo-7-(2-butynyl)-3-methyl-1-purine-2,6-dione with 2-chloromethyl-4-methylquinazoline to obtain a reaction liquid; reacting the reaction liquid with (R)-3-tert-butyloxycarboryl-aminopiperidine to obtain 8-[(3R)-3-(tert-butyloxycarboryl-amino)-1-piperidyl]-7-(2-butynyl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)-methyl]-1H-purine-2,6-dione. In the reacting process, an intermediate product is not separated. According to the preparation method, the intermediate product does not need to be separated or purified, the operation is simplified, the yield is high, the production cost is reduced, and the industrial production is benefited.
Owner:SUNSHINE LAKE PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products